Partial MHC/Neuroantigen Peptide Constructs: A Potential Neuroimmune-Based Treatment for Methamphetamine Addiction

Loftis, Jennifer M.; Wilhelm, Clare J.; Vandenbark, Arthur A.; Huckans, Marilyn
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Relapse rates following current methamphetamine abuse treatments are very high (∼40–60%), and the neuropsychiatric impairments (e.g., cognitive deficits, mood disorders) that arise and persist during remission from methamphetamine addiction likely contribute to these high relapse rates. Pharmacotherapeutic development of medications to treat addiction has focused on neurotransmitter systems with only limited success, and there are no Food and Drug Administration approved pharmacotherapies for methamphetamine addiction. A growing literature shows that methamphetamine alters peripheral and central immune functions and that immune factors such as cytokines, chemokines, and adhesion molecules play a role in the development and persistence of methamphetamine induced neuronal injury and neuropsychiatric impairments. The objective of this study was to evaluate the efficacy of a new immunotherapy, partial MHC/neuroantigen peptide construct (RTL551; pI-Ab/mMOG-35-55), in treating learning and memory impairments induced by repeated methamphetamine exposure. C57BL/6J mice were exposed to two different methamphetamine treatment regimens (using repeated doses of 4 mg/kg or 10 mg/kg, s.c.). Cognitive performance was assessed using the Morris water maze and CNS cytokine levels were measured by multiplex assay. Immunotherapy with RTL551 improved the memory impairments induced by repeated methamphetamine exposure in both mouse models of chronic methamphetamine addiction. Treatment with RTL551 also attenuated the methamphetamine induced increases in hypothalamic interleukin-2 (IL-2) levels. Collectively, these initial results indicate that neuroimmune targeted therapies, and specifically RTL551, may have potential as treatments for methamphetamine-induced neuropsychiatric impairments.


Related Articles

  • Identities of P2 and P3 Residues of H-2Kb-Bound Peptides Determine Mouse Ly49C Recognition. Marquez, Elsa A.; Kane, Kevin P. // PLoS ONE;7/6/2015, Vol. 10 Issue 7, p1 

    Ly49 receptors can be peptide selective in their recognition of MHC-I-peptide complexes, affording them a level of discrimination beyond detecting the presence or absence of specific MHC-I allele products. Despite this ability, little is understood regarding the properties that enable some...

  • Adaptive resistance to immunotherapy directed against p53 can be overcome by global expression of tumor-antigens in dendritic cells. Humar, Matjaz; Azemar, Marc; Maurer, Martina; Groner, Bernd // Frontiers in Oncology;Oct2014, Vol. 4, p1 

    Immunotherapy of cancer utilizes dendritic cells (DCs) for antigen presentation and the induction of tumor-specific immune responses. However, the therapeutic induction of anti-tumor immunity is limited by tumor escape mechanisms. In this study, immortalized dendritic D2SC/1 cells were...

  • Endoplasmic Reticulum Aminopeptidase-1 Functions Regulate Key Aspects of the Innate Immune Response. Aldhamen, Yasser A.; Seregin, Sergey S.; Rastall, David P. W.; Aylsworth, Charles F.; Pepelyayeva, Yuliya; Busuito, Christopher J.; Godbehere-Roosa, Sarah; Kim, Sungjin; Amalfitano, Andrea // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Endoplasmic reticulum aminopeptidase-1 (ERAP1) is a multifunctional, ubiquitously expressed enzyme whose peptide-trimming role during antigen processing for presentation by MHC I molecules is well established, however, a role for ERAP1 in modulating global innate immune responses has not been...

  • Forming a Complex with MHC Class I Molecules Interferes with Mouse CD1d Functional Expression. Gourapura, Renukaradhya J.; Khan, Masood A.; Gallo, Richard M.; Shaji, Daniel; Liu, Jianyun; Brutkiewicz, Randy R. // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    CD1d molecules are structurally similar to MHC class I, but present lipid antigens as opposed to peptides. Here, we show that MHC class I molecules physically associate with (and regulate the functional expression of) mouse CD1d on the surface of cells. Low pH (3.0) acid stripping of MHC class I...

  • Replication of Association between Schizophrenia and Chromosome 6p21-6p22.1 Polymorphisms in Chinese Han Population. Zhang, Yang; Lu, Tianlan; Yan, Hao; Ruan, Yanyan; Wang, Lifang; Zhang, Dai; Yue, Weihua; Lu, Lin // PLoS ONE;Feb2013, Vol. 8 Issue 2, p1 

    Chromosome 6p21-p22.1, spanning the extended major histocompatibility complex (MHC) region, is a highly polymorphic, gene-dense region. It has been identified as a susceptibility locus of schizophrenia in Europeans, Japanese, and Chinese. In our previous two-stage genome-wide association study...

  • An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platform. Fridman, Arthur; Finnefrock, Adam C.; Peruzzi, Daniela; Pak, Irene; Monica, Nicola La; Bagchi, Ansuman; Casimiro, Danilo R.; Ciliberto, Gennaro; Aurisicchio, Luigi // OncoImmunology;Nov2012, Vol. 1 Issue 8, p1258 

    Functional T-cell epitope discovery is a key process for the development of novel immunotherapies, particularly for cancer immunology. In silico epitope prediction is a common strategy to try to achieve this objective. However, this approach suffers from a significant rate of false-negative...

  • A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Epel, Malka; Ellenhorn, Joshua D.; Diamond, Don J.; Reiter, Yoram // Cancer Immunology, Immunotherapy;Nov2002, Vol. 51 Issue 10, p565 

    Specificity in the immune system is dictated and regulated by specific recognition of peptide/major histocompatibility complexes (MHC) by the T cell receptor (TCR). Such peptide/MHC complexes are a desirable target for novel approaches in immunotherapy because of their highly restricted fine...

  • Non-Canonical Peptides Bound to MHC. Day, Stephanie L.; Ramsland, Paul A.; Apostolopoulos, Vasso // Current Pharmaceutical Design;10/1/2009, Vol. 15 Issue 28, p3274 

    Central to the initiation of a T cell dependent immune response is the recognition of major histocompatibility complex (MHC) class I or class II molecules (in humans termed HLA and in mice termed H-2) bound to antigenic peptide. T cell receptors (TCR) have programmed specificity for particular...

  • Lower TCR repertoire diversity in Traj18-deficient mice. Bedel, Romain; Matsuda, Jennifer L; Brigl, Manfred; White, Janice; Kappler, John; Marrack, Philippa; Gapin, Laurent // Nature Immunology;Aug2012, Vol. 13 Issue 8, p705 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics